Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Operations: 2023-2025

Historic Cash from Operations for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to -$19.2 million.

  • Artiva Biotherapeutics' Cash from Operations fell 65.37% to -$19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$76.7 million, marking a year-over-year decrease of 50.18%. This contributed to the annual value of -$55.0 million for FY2024, which is 16.03% down from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Cash from Operations of -$19.2 million as of Q3 2025, which was up 16.46% from -$23.0 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Cash from Operations high stood at -$10.7 million for Q4 2023, and its period low was -$23.0 million during Q2 2025.
  • Its 3-year average for Cash from Operations is -$15.4 million, with a median of -$14.7 million in 2024.
  • Data for Artiva Biotherapeutics' Cash from Operations shows a maximum YoY plummeted of 67.94% (in 2025) over the last 5 years.
  • Artiva Biotherapeutics' Cash from Operations (Quarterly) stood at -$10.7 million in 2023, then tumbled by 37.24% to -$14.7 million in 2024, then plummeted by 65.37% to -$19.2 million in 2025.
  • Its Cash from Operations was -$19.2 million in Q3 2025, compared to -$23.0 million in Q2 2025 and -$19.8 million in Q1 2025.